|
Gene: ARMC3 |
Gene summary for ARMC3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ARMC3 | Gene ID | 219681 |
Gene name | armadillo repeat containing 3 | |
Gene Alias | CT81 | |
Cytomap | 10p12.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5W041 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
219681 | ARMC3 | RNA-P6T1-P6T1-1 | Human | Lung | MIAC | 3.00e-03 | 7.47e-01 | -0.0238 |
219681 | ARMC3 | RNA-P6T1-P6T1-2 | Human | Lung | MIAC | 4.12e-03 | 6.53e-01 | -0.0186 |
219681 | ARMC3 | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 3.47e-02 | 7.14e-01 | -0.0296 |
219681 | ARMC3 | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 2.24e-04 | 7.21e-01 | -0.0263 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Lung | AAH: Atypical adenomatous hyperplasia | |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | |
Stomach | GC | |
Stomach | CAG with IM | |
Stomach | CSG | |
Stomach | CAG |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARMC3 | SNV | Missense_Mutation | novel | c.2385N>G | p.Phe795Leu | p.F795L | Q5W041 | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-A7-A4SA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
ARMC3 | SNV | Missense_Mutation | novel | c.1737T>A | p.Asn579Lys | p.N579K | Q5W041 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARMC3 | SNV | Missense_Mutation | novel | c.1942N>A | p.His648Asn | p.H648N | Q5W041 | protein_coding | tolerated(0.31) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARMC3 | SNV | Missense_Mutation | c.2449N>T | p.Arg817Cys | p.R817C | Q5W041 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARMC3 | SNV | Missense_Mutation | c.946G>A | p.Glu316Lys | p.E316K | Q5W041 | protein_coding | deleterious(0.02) | possibly_damaging(0.761) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
ARMC3 | SNV | Missense_Mutation | c.1349C>T | p.Ser450Phe | p.S450F | Q5W041 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
ARMC3 | SNV | Missense_Mutation | c.588N>G | p.Ile196Met | p.I196M | Q5W041 | protein_coding | deleterious(0.04) | benign(0.12) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ARMC3 | insertion | Frame_Shift_Ins | novel | c.72_73insA | p.Ala27SerfsTer9 | p.A27Sfs*9 | Q5W041 | protein_coding | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ARMC3 | SNV | Missense_Mutation | novel | c.968C>T | p.Ala323Val | p.A323V | Q5W041 | protein_coding | tolerated(0.14) | benign(0.122) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ARMC3 | SNV | Missense_Mutation | c.1112N>T | p.Glu371Val | p.E371V | Q5W041 | protein_coding | tolerated(0.08) | probably_damaging(0.968) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |